Filter by business model, region, score band and the documents each supplier publishes.
Loading directory…
Vadodara drug maker, dating to 1907, with three API plants and six formulation plants. Holds US DMFs for 6 peptide APIs, including glatiramer and tirzepatide.
Bengaluru biopharma company that makes generic APIs and complex formulations, including GLP-1 peptides. Holds US DMFs for liraglutide, semaglutide and tirzepatide.
Changzhou API and tablet maker founded 1949 with a record of US FDA, EU GMP and PMDA inspections; US DMFs for semaglutide and tirzepatide.
Mumbai drugmaker founded in 1936 with six plants, including a US-FDA-accredited API site at Roha; holds an active US DMF for semaglutide.
Chinese maker of generic small-molecule, peptide and oligonucleotide APIs, founded in 1998, with an FDA-inspected site in Yangzhou. Holds US DMFs for semaglutide and tirzepatide.
Chinese peptide drug manufacturer producing APIs and finished products.
Belgian biotech firm and CDMO, part of Kaneka, selling research peptides, oligos and antibodies and running GMP manufacturing that it says is FDA inspected.
Beijing API company, founded 2006, that holds DMFs and has its APIs made in partner facilities under its own quality control. Holds US DMFs for 13 peptide APIs.
US generics, specialty and biosimilars company with operations in the US, India and Ireland; US DMF for glatiramer acetate.
Nanjing API subsidiary of Nasdaq-listed Amphastar; US DMF for teriparatide.
Fremont, California peptide maker founded in 1993, now a subsidiary of Kaneka Eurogentec, offering catalogue, custom and GMP-grade peptides and assay kits.
Texas custom synthesis company in business since 1984, making peptides, oligonucleotides and bioconjugates at its Lewisville facility.
Hyderabad API developer and maker founded in 2007, focused on niche and complex products. Holds US DMFs for cetrorelix, icatibant and sincalide.
Italian API maker in the Italfarmaco Group, founded 1973, producing peptides since 1996; US DMFs for leuprolide and octreotide.
Chongqing maker of diabetes and obesity drugs, active since 2015 and controlled by Zhifei (300122) since 2025; US DMFs for liraglutide and semaglutide.
Life-science services company with a large custom peptide synthesis service.
Hangzhou recombinant drug maker listed in Hong Kong (02566), formerly Huadong Medicine's gene engineering centre; US DMF for liraglutide.
Hangzhou drug maker incorporated 1993, part of Shenzhen-listed Huadong Medicine; two group entities hold US DMFs for semaglutide.
Main operating subsidiary of Hong Kong-listed Hansoh Pharma, founded 1995; holds US DMFs for degarelix and icatibant.
Osaka-based maker of research peptides, glyco compounds and amino acid reagents since 1977, also offering custom synthesis and GMP peptide drug development.
German peptide maker founded in 2001 near Berlin, selling catalogue peptides and peptide pools and offering custom synthesis on in-house built synthesis robots.
Korean peptide drug developer founded in 1997 that also runs an ISO 9001-certified custom peptide synthesis service and markets a 3.75 mg depot injection.
Heidelberg company founded in 2000 that synthesizes custom peptides and produces specific antibodies from the Heidelberg Technology Park.
Shenzhen-listed drug maker (002294) selling APIs and finished products; US DMF for bivalirudin.
Thermo Scientific custom peptide service making research peptides of 2-110 amino acids by Fmoc solid-phase synthesis, plus peptide libraries and AQUA heavy peptides.
Dubai-incorporated subsidiary of Zydus Lifesciences, the Ahmedabad drug group listed in India; US DMF for semaglutide.
UK lab in Redditch that synthesizes custom research peptides and peptide libraries and also runs UKAS-accredited amino acid analysis and protein sequencing.
Beijing biotech founded in 2018 that develops and produces recombinant protein and peptide drugs in E. coli for metabolic disease; holds an active US DMF for semaglutide.
Canadian life science research supplier, headquartered in Markham, Ontario and Amherst, New York, offering custom and GMP peptide and oligo synthesis.
Swiss Debiopharm plant in Martigny making triptorelin sustained-release products; US DMF for triptorelin pamoate microgranules.
Shanghai bulk peptide maker supplying wholesalers; holds US DMFs for bremelanotide, semaglutide and tirzepatide.
Putian, Fujian peptide API maker founded in 2019 by New Hope and Taiwan's Genovior, focused on GLP-1 APIs. Holds US DMFs for semaglutide and tirzepatide.
Shanghai maker of protected amino acids, custom and catalogue peptides, drug peptides, cosmetic peptides and antibodies, with eight production bases.
Privately held Hyderabad generics and API group with 36+ plants; US DMFs for semaglutide and vasopressin.
Tübingen peptide company with about 30 years in peptide synthesis, making custom peptides, libraries, arrays, PNAs and neoantigen vaccine peptides.
Changchun biopharmaceutical maker of somatropin, semaglutide and other APIs; holds active US DMFs for semaglutide and somatropin.
Berlin peptide maker offering custom synthesis, peptide catalogues, peptide pools, microarrays and pre-GMP peptides, with a TÜV Rheinland-certified ISO 9001 system.
New Jersey contract research company founded in 2008 that makes custom peptides, peptide conjugates and PNAs, and also provides protein and antibody services.
Nanjing supplier of insulin and metabolic peptide APIs with technology transfer services; US DMFs for semaglutide and tirzepatide.
UK custom peptide maker trading as Peptide Synthetics. It says it synthesizes every peptide in its own Hampshire laboratory and outsources none.
Weihai Sino-US joint venture founded 2016 making peptide APIs and cosmetic peptides; US DMFs for leuprolide and semaglutide.
Navi Mumbai biopharma and specialty pharma company; US DMFs for lanreotide and liraglutide.
Shenzhen peptide company founded in 2020 making GLP-1 peptide APIs, sterile vials and peptide reference materials at a Zhongshan plant; holds an active US DMF for tirzepatide.
Shenzhen synthetic-biology ingredient maker with semaglutide as its lead biopharma product; US DMFs for semaglutide main chain and side chain.
Leshan-based peptide producer founded in 2015 with SPPS and LPPS lines; holds US DMFs for eptifibatide, semaglutide and tirzepatide.
Hangzhou company founded in 2020 that makes GLP-1 peptides by fermentation plus semi-synthesis; holds an active US DMF for semaglutide API.
Mumbai drug maker incorporated in 1935 with plants in India and the USA. Holds US DMFs for difelikefalin, icatibant and terlipressin. Pithampur FDA warning letter still open.
Harbin peptide API maker founded in 2011. Holds US DMFs for 11 peptide APIs. FDA issued it a CGMP warning letter in May 2026 that remains open.
Nanjing maker of peptide, protein and polysaccharide APIs and finished products, registered in 2017. Holds US DMFs for semaglutide and tirzepatide. FDA warning letter issued Nov 2026.
Mumbai-based generics group that makes APIs and finished medicines. Holds US Type II DMFs for 15 peptide APIs, including GLP-1s and GnRH analogues.
Mumbai drug maker with its own API and formulation plants in India. Holds US DMFs for 3 peptide APIs. Received an FDA CGMP warning letter in November 2026.
Large Zhejiang API and generic drug maker founded in 1989 and listed in Shanghai; holds active US DMFs for semaglutide and a semaglutide intermediate. It has an open FDA warning letter from June 2025.